clearly distinguished from the other samples analyzed, and displayed a 1.5-2-fold greater increase in cell number, mainly at the later time points of the curve (Figure 1b, Supplementary Figure 1b), and reduced response to the antiproliferative effect of rapamycin, a specific mTOR inhibitor (Figure 1c, Supplementary Figure 1c). Curiously, whereas dual PI3K-mTOR inhibition (wortmannin+rapamycin treatment) continued to be less effective in reducing to a similar extent the proliferation of ASD1-2 and control cells, it was able to restore the enhanced proliferation of ASD3 cells (Figure 1c, Supplementary Figure 1c), suggesting a possible different regulatory mechanism in ASD3 cells. Knockout mouse models of both syndromic and nonsyndromic ASD with disinhibited mTOR signaling and dysregulated protein synthesis present dysplastic and enlarged neurons with increased spine density in several brain regions.<sup>5,7,8</sup> Although we did not notice increased ASD1-3 SHED volumes, it will now be important to determine and explore further whether the altered proliferative phenotype observed in these cells may also be observed in neuronal cell types, which could be a potential additional mechanism whereby disrupted mTORC1 signaling contributes to ASD neuropathology.

Conventional karyotyping and analysis of copy number variations at 15q11-q13, 16p11 and 22q13, found to occur more often in ASD, did not reveal any genomic aberrations in all patients except ASD3, who presents an inverted duplication of 15q11-q13. It is possible that genes located at this region may contribute to the aberrant molecular and cellular phenotypes observed in ASD3 cells. In addition, TSC1/2, FMR1, PTEN, NF1 and MeCP2 genes (ASD-associated genes known to be negative regulators of PI3K-mTOR signaling pathway) were screened for coding and splice-site mutations in ASD1-13 patients and no potentially deleterious variants were identified. Therefore, the causative genetic architecture underlying mTORC1 overactivity in ASD1-3 cells remains to be determined. It is also noteworthy that patients ASD1-3, who seem to some extent share overlapping pathophysiological mechanisms, show different degree of cognitive and social impairments: ASD1 was diagnosed with Asperger syndrome and ASD2-3 with low-functioning autism (Supplementary Table S1), suggesting that other genetic and environmental modifier factors may also have a role in cognitive development in these patients.

In conclusion, our results suggest that dysregulation of mTORC1 signaling has an important role in the pathogenesis of a subgroup of nonsyndromic ASD, and that mTOR pathway components might be promising therapeutic targets for these patients. Importantly, during the revision process of this manuscript, it was reported hyperactivated mTOR signaling in postmortem brain tissue from both adolescent patients with idiopathic ASD<sup>9</sup> and 15q11-q13 duplication patients with ASD,<sup>10</sup> which provide further strong support for this hypothesis. Finally, our results suggest that SHEDs are an alternative and more readily accessible source of patient material to study disease pathophysiology and to refine treatment approaches for individual patients.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

AM Suzuki<sup>1</sup>, K Griesi-Oliveira<sup>1,2</sup>, C de Oliveira Freitas Machado<sup>2</sup>, E Vadasz<sup>3</sup>, EC Zachi<sup>1</sup>, MR Passos-Bueno<sup>1</sup> and AL Sertie<sup>2</sup> <sup>1</sup>Centro de Pesquisa sobre o Genoma Humano e Células-Tronco, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brasil; <sup>2</sup>Hospital Israelita Albert Einstein, Centro de Pesquisa Experimental, São Paulo, Brasil and

<sup>3</sup>Instituto de Psiquiatria, Hospital das Clinicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil E-mail: andrea.sertie@einstein.br or sertiea@gmail.com

#### REFERENCES

- 1 Kelleher RJ 3rd, Bear MF. Cell 2008; 135: 401-406.
- 2 Ebert DH, Greenberg ME. Nature 2013; 493: 327-337.
- 3 Auerbac BD, Osterweil EK, Bear MF. Nature 2011; 480: 63-68.
- 4 Hoeffer CA, Sanchez E, Hagerman RJ, Mu Y, Nguyen DV, Wong H et al. Genes Brain Behav 2012; 11: 332–341.
- 5 Gkogkas CCG, Khoutorsky A, Ran I, Rampakakis E, Nevarko T, Weatherill DB et al. Nature 2013; 493: 371–377.
- 6 Griesi-Oliveira K, Sunaga DY, Alvizi L, Vadsz E, Passos-Bueno MR. *Autism Res* 2013; 6: 354–361.
- 7 Meikle L, Talos DM, Onda H, Pollizzi K, Rotenberg A, Sahin M et al. J Neurosci 2007; 27: 5546–5558.
- 8 Zhou J, Blundell J, Ogawa S, Kwon CH, Zhang W, Sinton C *et al. J Neurosci* 2009; **29**: 1773–1783.
- 9 Tang G, Gudsnuk K, Kuo SH, Cotrina ML, Rosoklija G, Sosunov A *et al. Neuron* 2014; **83**: 1–13.
- 10 Oguro-Ando A, Rosensweig C, Herman E, Nishimura Y, Werling D, Bill BR et al. Mol Psychiatry. advance online publication, 14 October 2014; doi:10.1038/ mp.2014.124 (e-pub ahead of print).

Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)

# **OPEN**

# Resilience after 3/11: structural brain changes 1 year after the Japanese earthquake

*Molecular Psychiatry* (2015) **20,** 552–554; doi:10.1038/mp.2014.28; published online 29 April 2014

Stressful events can have both short- and long-term effects on the brain.<sup>1,2</sup> A recent investigation by our lab identified regional grey matter volume (rGMV) changes in people in the months following the Japanese earthquake.<sup>3</sup> These findings indicated that smaller anterior cingulate cortex volume was a preexisting vulnerability factor for posttraumatic stress disorder (PTSD) symptoms and that decreased volume of the orbitofrontal cortex (OFC) was a result of these acquired symptoms.<sup>3</sup> These types of symptoms were regarded as manifestations of the short-term effects of post-earthquake stress. However, the long-lasting effects of stressful events on brain structures remain unclear. Thus, this study examined the 1-year prognoses of subjects after a stressful event to clarify the long-term effects of stress on structural brain changes.

Of the 42 subjects included in our previous study,<sup>3</sup> 37 subjects (male/female (M/F) = 28/9, age =  $21.0 \pm 1.6$  years) were recruited for a third time, and their structural magnetic resonance imaging (MRI) scans were evaluated 1 year after the earthquake. The optimized voxel-based morphometry (VBM) method for a brain structural data set (for greater detail, see Sekiguchi *et al.*,<sup>3</sup>) was applied, and rGMVs from before (Pre), soon after (Post) and at the 1-year follow-up (Follow-up) of the earthquake were compared using conjunction analyses. In addition, we also assessed the subjects' psychological characteristics, including anxiety, depression, posttraumatic growth and self-esteem. Furthermore, we



**Figure 1.** (a) Right hippocampal volumes significantly decreased from Pre to Post and from Post to Follow-up and (b) bilateral and medial orbitofrontal cortex (OFC) volumes significantly increased from Pre to Post and from Post to Follow-up. These regional grey matter volume (rGMV) changes are illustrated by the plots on the right side, where vertical axes represent rGMV at peak voxels in each cluster, and horizontal axes indicate time periods. Error bars represent s.d. values. Blt, biltateral; Lt, left; Rt, right.

collected longitudinal brain structural MRI data from 11 normal controls (M/F = 7/4, age =  $20.2 \pm 1.0$  years) obtained on at least two occasions before the earthquake (see Supplementary Methods for additional details).

At 1 year after the earthquake, none of the subjects in this study had developed clinical PTSD, whereas other psychological measures did not significantly change from Post to Follow-up (see Supplementary Table S1). In terms of rGMV, bilateral and medial OFC volumes significantly increased (P < 0.05; small-volume correction, SVC), and right hippocampal volumes significantly decreased (P < 0.05, SVC) from Pre and Post to Follow-up (Figure 1; Supplementary Table S2), whereas the control subjects did not show above-mentioned rGMV changes between two time points. *Post hoc* correlation analyses revealed that the increase in the volume of the left OFC from Post to Follow-up was significantly correlated with self-esteem scores at Post (r = 0.43, P = 0.007; Supplementary Table S3).

The increase in OFC volume identified in some subjects who reported stress indicates that recovery from emotional distress is possible following a stressful event. Previous neuroimaging findings have shown that a reduction in OFC volume is a sign of emotional distress following stressor,<sup>3</sup> but stress-induced structural and functional alterations in the OFC are reversible.<sup>4</sup> Although the left OFC volume in our subjects experiencing PTSD symptoms soon after the earthquake decreased in the short term,<sup>3</sup> the mean OFC volumes increased during this period (Figure 1b), which is consistent with previous findings soon after a disaster.<sup>5</sup> Moreover, the results provide an initial indication that the increased left OFC volume was caused by higher self-esteem. Given that higher self-esteem is one of the most important traits of resilience in the context of stressful life events,<sup>6</sup> it is possible that self-esteem is a predictor of increased OFC volume, representing the successful regulation of emotional distress after the earthquake by healthy survivors.

In contrast, stress related to the earthquake may persist even after 1 year. Psychological evaluations at 1 year revealed that even subclinical levels of depression and anxiety levels had not improved from soon after the earthquake. Hippocampal volume reduction is a robust finding in traumatized subjects,<sup>7</sup> and is observed even in subjects with subclinical depression after a disaster.<sup>5</sup> Even if the hippocampal volume of young healthy adults were not significantly but slightly reduced as a function of aging (see Supplementary Discussion), post-earthquake stress would accelerate the hippocampal volume reduction because agerelated reduction is modified by PTSD and depression.<sup>8</sup> Together, these findings led us to hypothesize that both prolonged stress and aging affect a reduction in hippocampal volume over time, whereas short-term stress does not reduce hippocampal volume in the period immediately following stressful events such as earthquakes<sup>3</sup> (see Supplementary Discussion).

The limitations of this study included the absence of psychological assessments and incomplete profiles for the control subjects (see Supplementary Discussion).

Despite these limitations, the present follow-up VBM study found that stressful events had long-lasting effects on various brain structures, suggesting that such changes are influenced by prolonged stress and self-esteem characteristics. Here, it was assumed that structural changes in the brain following stressful life events are not static, but dynamic, throughout one's lifetime. Recently, altered functional and structural connectivity, including in regions adjacent to the OFC and hippocampus as well as in the insula, basal ganglia and parietal lobe,<sup>9,10</sup> have been reported soon after a disaster. Therefore, further longitudinal investigations using multimodal approaches are necessary to examine whether the stress-induced alterations in brain structure are reversible (see Supplementary Discussion).

#### **CONFLICT OF INTEREST**

The authors declare no conflict of interest.

#### AUTHOR CONTRIBUTIONS

All authors contributed to the concept and design of the study. AS, YK, MS, TA, SH, SN, and CMM contributed to data acquisition. AS, MS, YK, RN, HT, TA, YT and RK contributed to the data analysis and interpretation. AS, MS, RN, HT, TA, YT and RK provided statistical expertise. AS wrote the manuscript. MS, RN, HT, YT and RK reviewed/revised the manuscript. All authors discussed the results and commented on the manuscript. All authors gave their final approval for the manuscript to be submitted.

A Sekiguchi<sup>1,2</sup>, Y Kotozaki<sup>3</sup>, M Sugiura<sup>2,4</sup>, R Nouchi<sup>3,4</sup>, H Takeuchi<sup>5</sup>, S Hanawa<sup>2</sup>, S Nakagawa<sup>2</sup>, CM Miyauchi<sup>2,6</sup>, T Araki<sup>3</sup>, A Sakuma<sup>2,7</sup>, Y Taki<sup>1,5,8</sup> and R Kawashima<sup>2,3,5</sup>

<sup>1</sup>Division of Medical Neuroimage Analysis, Department of Community Medical Supports, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan;

<sup>2</sup>Department of Functional Brain Imaging, Institute of Development, Aging and Cancer (IDAC), Tohoku University, Sendai, Japan;

<sup>3</sup>Department of Advanced Brain Science, Smart Ageing International Research Center, IDAC, Tohoku University, Sendai, Japan; <sup>4</sup>International Research Institute of Disaster Science, Tohoku

University, Sendai, Japan;

<sup>5</sup>Division of Developmental Cognitive Neuroscience, IDAC, Tohoku University, Sendai, Japan;

<sup>6</sup>Graduate Schools for Law and Politics, The University of Tokyo, Tokyo, Japan;

<sup>7</sup>Department of Psychiatry, Tohoku University Graduate School of Medicine, Sendai, Japan and

<sup>8</sup>Department of Nuclear Medicine and Radiology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan E-mail: asekiguchi@idac.tohoku.ac.jp

# 554

### REFERENCES

- 1 van Wingen GA, Geuze E, Vermetten E, Fernandez G. *Mol Psychiatry* 2011; 16: 664–671.
- 2 van Wingen GA, Geuze E, Vermetten E, Fernandez G. *Mol Psychiatry* 2012; **17**: 116–118.
- 3 Sekiguchi A, Sugiura M, Taki Y, Kotozaki Y, Nouchi R, Takeuchi H et al. Mol Psychiatry 2013; 18: 618–623.
- 4 Liston C, McEwen BS, Casey BJ. Proc Natl Acad Sci USA 2009; 106: 912-917.
- 5 Lui S, Chen L, Yao L, Xiao Y, Wu QZ, Zhang JR et al. J Psychiatry Neurosci 2013; 38: 120244.
- 6 Rutter M. Br J Psychiatry 1985; 147: 598-611.
- 7 Woon FL, Sood S, Hedges DW. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1181–1188.

- 8 Fotuhi M, Do D, Jack C. Nat Reiews Neurology 2012; 8: 189-202.
- 9 Lui S, Huang X, Chen L, Tang H, Zhang T, Li X *et al. Proc Natl Acad Sci USA* 2009; **106**: 15412–15417.
- 10 Chen L, Lui S, Wu QZ, Zhang W, Zhou D, Chen HF *et al. Hum Brain Mapp* 2013; **34**: 367–373.

This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http:// creativecommons.org/licenses/by/3.0/

Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)